Aralez Pharm Inc (ARLZ) 5.47 $ARLZ IIROC Trade
Post# of 273242
IIROC Trade Resumption - ARZ
CNW Group - Thu Sep 15, 8:44AM CDT
Trading resumes in:
ARZ.TO: 7.25 (-0.24), ARLZ: 5.47 (-0.17)
IIROC Trade Resumption - Aralez Pharmaceuticals Inc.
Newsfile Corp - Thu Sep 15, 8:41AM CDT
Trading resumes in:
ARLZ: 5.47 (-0.17)
Aralez Announces FDA Approval Of YOSPRALA For Secondary Prevention Of Cardiovascular And Cerebrovascular Events In Patients At Risk For Aspirin-Associated Gastric Ulcers
PR Newswire - Thu Sep 15, 8:33AM CDT
Aralez Sales Force Will Be Expanded by 85 to 110 Sales Representatives by Launch-
ARZ.TO: 7.25 (-0.24), ARLZ: 5.47 (-0.17)
IIROC Trading Halt - ARZ
CNW Group - Thu Sep 15, 6:37AM CDT
The following issues have been halted by IIROC:
ARZ.TO: 7.25 (-0.24), ARLZ: 5.47 (-0.17)
IIROC Trade Halt - Aralez Pharmaceuticals Inc.
Newsfile Corp - Thu Sep 15, 6:35AM CDT
The following issues have been halted by IIROC:
ARLZ: 5.47 (-0.17)
Aralez Acquires United States And Canadian Rights To ZONTIVITY From Merck
PR Newswire - Wed Sep 07, 7:35AM CDT
Acquired ZONTIVITY® in the U.S. and Canada-
MRK: 61.33 (-0.95), ARZ.TO: 7.25 (-0.24), ARLZ: 5.47 (-0.17)
Aralez Reports Second Quarter 2016 Financial Results
CNW Group - Tue Aug 09, 7:00AM CDT
Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company" today announced financial results for the second quarter ended June 30, 2016. The Company also highlighted certain corporate, commercial, and regulatory updates. All figures are in U.S. dollars.
ARZ.TO: 7.25 (-0.24), ARLZ: 5.47 (-0.17)
Research Report Coverage on Select Biotech Stocks -- Vertex Pharma, Infinity Pharma, Aduro BioTech, and Aralez Pharma
PR Newswire - Mon Aug 01, 7:05AM CDT
The Biotech industry is where investors come out either short or confidently strong. Following its fall in September 2015, the industry is now signaling a pullback, suggesting to the investor community that buying opportunities are available. Additionally, the sector finished on a solid note in July 2016, up 10%. Today, Stock-Callers.com has the following equities on its radar for further assessment: Vertex Pharmaceuticals Inc. (NASDAQ: VRTX), Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Aduro BioTech Inc. (NASDAQ: ADRO), and Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ). These stocks research reports can be downloaded now by simply registering for free at:
VRTX: 91.26 (-1.45), ADRO: 14.47 (-0.20), ARLZ: 5.47 (-0.17), INFI: 1.49 (+0.03)
Pre-market Equity Watch on Biotechnology -- Infinity Pharma, Nektar Therapeutics, Aralez Pharma, and BIND Therapeutics
PR Newswire - Thu Jun 23, 7:20AM CDT
On Wednesday, June 22, 2016, the NASDAQ Composite ended the trading session at 4,833.32, down 0.22%; the Dow Jones Industrial Average edged 0.27% lower to finish at 17,780.83; and the S&P 500 closed at 2,085.45, down 0.17%. Stock-Callers.com has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. (NASDAQ: INFI), Nektar Therapeutics (NASDAQ: NKTR), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ), and BIND Therapeutics Inc. (NASDAQ: BIND). Learn more about these stocks by accessing their free trade alerts at:
BIND: 0.78 (-0.09), ARLZ: 5.47 (-0.17), INFI: 1.49 (+0.03), NKTR: 18.99 (-0.09)